| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Pediatrics (J.L.F., R.C.B., K.M.T.), University of Arkansas for Medical Sciences and Arkansas Childrens Hospital Research Institute, Little Rock, Arkansas 72202; Department of Pediatrics (D.M.S.), Duke University Medical Center, Durham, North Carolina 27710; Department of Molecular and Structural Biology (J.J.E.), University of Aarhus, DK-8000 Aarhus C, Denmark; and Kennedy Institute of Rheumatology Division (H.N.), Faculty of Medicine, Imperial College London, London W6 8LH, United Kingdom
Address all correspondence and requests for reprints to: John L. Fowlkes, M.D., Professor and Chief, Division of Pediatric Endocrinology and Diabetes, University of Arkansas for Medical Sciences, Arkansas Childrens Hospital, Arkansas Childrens Hospital Research Institute, 800 Marshall Street, Slot 512-6, Little Rock, Arkansas 72202. E-mail: fowlkesjohnl{at}uams.
IGF-I and IGF-II play important roles in growth and development via interactions with cell-surface receptors; however, in nature, IGFs are sequestered by at least six soluble, high-affinity IGF-binding proteins (IGFBPs), namely IGFBPs 16. Herein, we demonstrate that the stromal cell-derived extracellular matrix-degrading metalloproteinase stromelysin 1 (matrix metalloproteinase 3) disrupts IGF/IGFBP-3 complexes and liberates free, intact IGFs, leading to phosphorylation of cell surface type 1 IGF receptors and cellular proliferation. Tissue inhibitor of metalloproteinases (TIMP-1) or an antibody to the type 1 IGF receptor mitigates IGF-mediated cellular proliferation. Thus, these studies suggest that matrix metalloproteinases, beyond their effects on extracellular matrix turnover, regulate cellular proliferation by modulating the bioavailability of IGFs, an event critical for such diverse phenomena as embryo development, morphogenesis, angiogenesis, and tumorigenesis.
This article has been cited by other articles:
![]() |
P. H. Larsen, A. G. DaSilva, K. Conant, and V. W. Yong Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J. Neurosci., February 22, 2006; 26(8): 2207 - 2214. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ii, H. Yamamoto, Y. Adachi, Y. Maruyama, and Y. Shinomura Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer Invasion, Apoptosis, Growth, and Angiogenesis Experimental Biology and Medicine, January 1, 2006; 231(1): 20 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Stephens, P. McElduff, A. H. Heald, J. P. New, J. Worthington, W. E. Ollier, and J. M. Gibson Polymorphisms in IGF-Binding Protein 1 Are Associated With Impaired Renal Function in Type 2 Diabetes Diabetes, December 1, 2005; 54(12): 3547 - 3553. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ogawa, T. Nikawa, H. Furochi, M. Kosyoji, K. Hirasaka, N. Suzue, K. Sairyo, S. Nakano, T. Yamaoka, M. Itakura, et al. Osteoactivin upregulates expression of MMP-3 and MMP-9 in fibroblasts infiltrated into denervated skeletal muscle in mice Am J Physiol Cell Physiol, September 1, 2005; 289(3): C697 - C707. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Hemers, C. Duval, C. McCaig, M. Handley, G. J. Dockray, and A. Varro Insulin-Like Growth Factor Binding Protein-5 Is a Target of Matrix Metalloproteinase-7: Implications for Epithelial-Mesenchymal Signaling Cancer Res., August 15, 2005; 65(16): 7363 - 7369. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Gharib, D. L. Luchtel, D. K. Madtes, and R. W. Glenny Global gene annotation analysis and transcriptional profiling identify key biological modules in hypoxic pulmonary hypertension Physiol Genomics, June 16, 2005; 22(1): 14 - 23. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |